Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

A healthcare worker holds up an AstraZeneca vaccine.

An illustrative image of a person holding a medical syringe and a vaccine vial in front of the AstraZeneca logo on October 21, 2021 in Edmonton, Alberta, Canada. (Photo: Artur Widak/NurPhoto via Getty Images)

Outrage as AstraZeneca Ditches Pledge Not to Profit From Publicly Funded Vaccine

"AstraZeneca's decision to start profiting from Oxford University's coronavirus vaccine mid-pandemic shows the utter folly of giving away publicly funded science to Big Pharma."

Jake Johnson

The multinational pharmaceutical giant AstraZeneca drew immediate backlash Friday for announcing an end to its pledge not to profit from its publicly funded coronavirus vaccine until the end of the pandemic, which is still killing more than 7,000 people worldwide each day.

"Corporations will always put profits first if you give them control over who lives and who dies."

Developed in partnership with the University of Oxford, the AstraZeneca vaccine was almost entirely financed by taxpayers and charitable trusts, with just around 2% of the money coming from private industry.

Nick Dearden, director of the U.K.-based advocacy group Global Justice Now, said in a statement that "AstraZeneca's decision to start profiting from Oxford University's coronavirus vaccine mid-pandemic shows the utter folly of giving away publicly funded science to Big Pharma."

"The non-profit pledge was never a gift to the world from a benevolent company," said Dearden. "It was the most Oxford could get from a manufacturer playing hardball during a global health emergency. And AstraZeneca has still refused to share the vaccine recipe with the [World Health Organization], which would allow poorer countries to manufacture it for themselves."

"This moment was always going to come—and it's exactly why public health experts have demanded a waiver of intellectual property on Covid-19 vaccines," he continued. "Corporations will always put profits first if you give them control over who lives and who dies."

In a press release on Friday, AstraZeneca said it expects to "progressively transition the vaccine to modest profitability as new orders are received." The company said the shot generated just over $1 billion in revenue in the third quarter.

The Financial Times reported that AstraZeneca's shot will "remain non-profit for developing countries," but the company's contract with the University of Oxford gives it the ability to charge some low-income nations higher prices once it decides the pandemic has ended.

Pascal Soriot, AstraZeneca's CEO, claimed Friday that Covid-19 "is becoming endemic, which means we have to learn to live with it."

According to a recent report by Amnesty International, AstraZeneca has delivered more coronavirus vaccine doses to lower-income countries than its major competitors, including Pfizer and Moderna—both of which reported major vaccine profits in the third quarter. AstraZeneca has also "issued some voluntary licenses to other manufacturers," the humanitarian group observed.

"However," Amnesty noted, "it has refused to openly share its knowledge and technology with WHO initiatives and has opposed" India and South Africa's proposed patent waiver.

Anna Marriott, health policy manager at Oxfam International, said in a statement Friday that AstraZeneca is "breaking its repeated and celebrated public promises of a non-profit vaccine for all countries for the duration of this pandemic and to never to make a profit in any low- and middle-income country from this publicly funded vaccine."

"Broken promises from pharmaceutical corporations and rich country governments have been an enduring theme of this pandemic when it comes to vaccine access," Marriott added. "This is a further example of why the U.K. government can no longer defend the pharmaceutical monopolies driving today's vaccine apartheid."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

... We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.

As SCOTUS Considers 'Extinguishing' Right to Abortion, Calls Mount for Congress to 'Step Up'

"Despite the protections that the legal framework like Roe provides, it has never been enough," said one doctor. "We continue to work toward reproductive justice."

Jessica Corbett ·


US Must Tackle Marine Plastics Pollution 'From Source to Sea': Report

The National Academies of Sciences, Engineering, and Medicine study found that the U.S. is responsible for about a quarter of the plastics that enter the world's oceans each year.

Brett Wilkins ·


First US Omicron Case Confirmed as WHO Chief Decries Failure to Share Vaccines Globally

Factors including low vaccine coverage have created "a recipe for breeding and amplifying variants," the top health official said.

Andrea Germanos ·


Since Congress Lifted Crude Export Ban in 2015, US Has Dropped 'Climate Bomb' on World

Oil and gas exports from the Gulf Coast have surged by nearly 600%, and fossil fuel production in the Permian Basin has grown by 135%.

Kenny Stancil ·


Marking World AIDS Day, Campaigners Warn 'History Is Repeating Itself With Covid'

"In Africa alone, it's estimated up to 12 million people died needlessly in the time it took to make HIV treatment universally available. We cannot allow it to happen again with Covid-19."

Jake Johnson ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo